I agree that this site is using cookies. You can find further informations here.
X
Jonathan R. Chabon
28  results:
Search for persons X
?
1

Loss of H3K36 Methyltransferase SETD2 Impairs V(D)J Recombi..:

Chu, S. Haihua ; Chabon, Jonathan R. ; Matovina, Chloe N....
iScience.  23 (2020)  3 - p. 100941 , 2020
Link: https://doi.org/10.1016/..
 
?
2

Inhibition of MEK and ATR is effective in a B-cell acute ly..:

Chu, S. Haihua ; Song, Evelyn J. ; Chabon, Jonathan R....
Blood Advances.  2 (2018)  19 - p. 2478-2490 , 2018
Link: https://doi.org/10.1182/..
 
?
3

Loss of H3K36 Methyltransferase SETD2 Impairs V(D)J Recombi..:

S. Haihua Chu ; Jonathan R. Chabon ; Chloe N. Matovina...
http://www.sciencedirect.com/science/article/pii/S2589004220301255.  , 2020
Link: https://doi.org/10.1016/..
 
?
4

Loss of H3K36 Methyltransferase SETD2 Impairs V(D)J Recombi..:

Chu, S. Haihua ; Chabon, Jonathan R ; Matovina, Chloe N...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066224/.  , 2020
Link: http://www.ncbi.nlm.nih...
 
?
5

Inhibition of MEK and ATR is effective in a B-cell acute ly..:

Chu, S. Haihua ; Song, Evelyn J ; Chabon, Jonathan R...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177652/.  , 2018
Link: http://www.ncbi.nlm.nih...
 
?
6

Systemic Immunity Is Required for Effective Cancer Immunoth..:

Spitzer, Matthew H. ; Carmi, Yaron ; Reticker-Flynn, Nathan E....
Cell.  168 (2017)  3 - p. 487-502.e15 , 2017
Link: https://doi.org/10.1016/..
 
?
7

Systemic immunity is required for effective cancer immunoth..:

Spitzer, Matthew H ; Carmi, Yaron ; Reticker-Flynn, Nathan E...
info:eu-repo/semantics/altIdentifier/pmid/28111070.  , 2017
Link: https://hdl.handle.net/2..
 
?
8

Systemic Immunity Is Required for Effective Cancer Immunoth..:

Spitzer, Matthew H ; Carmi, Yaron ; Reticker-Flynn, Nathan E...
qt48g599js.  , 2017
Link: https://escholarship.org..
 
?
9

Systemic Immunity is Required for Effective Cancer Immunoth..:

Spitzer, Matthew H ; Carmi, Yaron ; Reticker-Flynn, Nathan E...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312823/.  , 2017
Link: http://www.ncbi.nlm.nih...
 
?
10

Akt and SHP-1 are DC-intrinsic checkpoints for tumor immuni..:

Carmi, Yaron ; Prestwood, Tyler R ; Spitzer, Matthew H...
qt4r9142ms.  , 2016
Link: https://escholarship.org..
 
?
11

Akt and SHP-1 are DC-intrinsic checkpoints for tumor immuni..:

Carmi, Yaron ; Prestwood, Tyler R ; Spitzer, Matthew H...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085602/.  , 2016
Link: http://www.ncbi.nlm.nih...
 
?
12

Evolution and clinical impact of co-occurring genetic alter..:

Blakely, Collin M ; Watkins, Thomas B K ; Wu, Wei...
Nature Genetics.  49 (2017)  12 - p. 1693-1704 , 2017
Link: https://doi.org/10.1038/..
 
?
13

Evolution and clinical impact of co-occurring genetic alter..:

Blakely, Collin M ; Watkins, Thomas BK ; Wu, Wei...
qt9gf2r305.  , 2017
Link: https://escholarship.org..
 
?
14

Evolution and clinical impact of co-occurring genetic alter..:

Blakely, Collin M ; Watkins, Thomas B.K ; Wu, Wei...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709185/.  , 2017
Link: http://www.ncbi.nlm.nih...
 
?
15

MRD‐NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYS..:

Roschewski, M. ; Kurtz, D. M. ; Westin, J....
Hematological Oncology.  41 (2023)  S2 - p. 177-179 , 2023
Link: https://doi.org/10.1002/..
 
1-15